title: [Treatment of cerebral ischemia in its acute phase and prospectives].
abstract: At the acute stage of cerebral ischemia, the "therapeutic window" probably does not last more than 6-12 hours. Despite similar treatments, patients admitted in stroke specialist units are more likely to survive and to have a good functional outcome than patients treated in general wards. In most cases acute arterial hypertension should not be treated. Thrombolytic agents given within 6 hours after onset, are now under evaluation in several clinical trials. There is no scientific evidence to support the use of anti-coagulation as a curative treatment of acute cerebral ischemia; however, clinical trials remain necessary, especially in progressing stroke. Neuroprotective drugs protect neurons against the consequences of hypoxia in animals: most clinical trials with oral nimodipine led to negative results but the meta-analysis suggests that patients receiving nimodipine within 12 hours after stroke onset might have a lower mortality rate and a better functional outcome. Other clinical trials with neuroprotective drugs are currently running: anti-NMDA drugs, chlomethiazol, tirilazad, ganglioside GM 1, etc Most therapeutic agents are now under evaluation. An early admission of patients with acute stroke is required to evaluate therapeutics agents which probably cannot be effective if started more than 6-12 hours after stroke onset.
authors.affiliation: Groupe neurovasculaire lillois, CHU de Lille, hôpital B, France.
authors.forename: D
authors.initials: D
authors.lastname: Leys
authors.forename: M
authors.initials: M
authors.lastname: Hommel
authors.forename: F
authors.initials: F
authors.lastname: Woimant
authors.forename: J P
authors.initials: JP
authors.lastname: Pruvo
mesh_terms: D000208:Acute Disease; D002545:Brain Ischemia / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D011379:Prognosis; D015424:Reperfusion
vernacular_title: Le traitement de l'ischémie cérébrale à la phase aiguë et ses perspectives.